Eiger gets FDA breakthrough therapy designation for avexitide

Eiger BioPharmaceuticals’ (NASDAQ:EIGR) avexitide received FDA breakthrough therapy designation for the treatment of post-bariatric hypoglycemia (PBH).

PBH is characterized by dangerously low blood glucose levels following a meal in post-bariatric surgical patients. Avexitide is a glucagon-like peptide 1 antagonist that is designed to normalize insulin secretion and reduce hypoglycemia following a meal.

“Our avexitide PBH clinical program has dosed 54 patients across four Phase 2 studies, involving both inpatient and outpatient treatment, with promising results for patients suffering from post-bariatric hypoglycemia,” David Cory, Eiger’s president and CEO, said in a statement.

Avexitide has received FDA and EMA orphan drug designation for the treatment of hyperinsulinemic hypoglycemia and non-insulinoma pancreatogenous hypoglycemia syndrome (NIPHS), respectively, both of which include the PBH indication.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.